alt

7th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2013)

June 30-July 3, 2013, Kuala Lumpur

IAS 2013: Combination Prevention Trial Shows Drop in HIV Incidence, Increase in Testing

Results from Project ACCEPT, a pioneering HIV prevention trial comparing the effects of mobile HIV testing, community mobilization, and enhanced support for people with HIV, versus standard voluntary counseling and testing, were announced at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Kuala Lumpur.

alt

Read more:

IAS 2013: Acute Retroviral Syndrome Linked to HIV Disease Progression

People who reported higher scores on a scale of symptom severity during initial HIV infection had lower CD4 T-cell counts, higher viral load set-points, and greater likelihood of HIV disease progression than those with mild or no acute antiretroviral symptoms, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more:

IAS 2013: Cost of HIV Drugs in Resource-limited Settings [VIDEO]

The price of first- and second-line antiretroviral medications has fallen in recent years, largely due to increased competition among generic drug producers, but the newest antiretrovirals continue to be priced out of reach of many who need them, according to a report released by Médecins Sans Frontières/Doctors Without Borders to coincide with the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more:

IAS 2013: Middle-income Countries Outside Africa Pay Four Times More for Antiretroviral Drugs

Middle-income countries outside Africa are paying, on average, 4 times more for antiretrovirals than African countries with similar gross national incomes (GNI), according to a study presented recently at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur.

alt

[Produced in collaboration with Aidsmap.com]

Read more:

IAS 2013: Stribild 'Quad' Pill Continues to Show Good Efficacy at 96 Weeks

The 4-in-1 Stribild single-tablet regimen maintains HIV viral load suppression through 96 weeks and remains generally well-tolerated, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur. Another study found that Stribild and its component cobicistat appear safe for people with mild-to-moderate kidney impairment.

alt

Read more: